RIGL

Rigel Pharmaceuticals, Inc.

RIGL | $1.035 -1.43% 430K

(0.0% 1d) (-26.1% 1m) (-11.8% 1y) (0.0% 2d) (-5.4% 3d) (-8.7% 7d) (114.12% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 181,543,826
http://www.rigel.com
Sec Filling | Patents | 163 employees

(US) Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

urea immunology msa

Drugs

TAVALISSE (FOSTAMATINIB)

add to watch list Paper trade email alert is off

Press-releases

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-04-10 (Crawled : 21:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -13.93% | O: 1.64% H: 2.02% C: -0.81%
nasdaq grants

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Published: 2024-04-04 (Crawled : 12:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -19.85% | O: 3.82% H: 0.0% C: -5.15%
rezlidhia publication aml leukemia

Health Technology

| -19.85% | O: 3.82% H: 0.0% C: -5.15%
rezlidhia publication aml leukemia

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Published: 2024-03-14 (Crawled : 14:30) - biospace.com/
LEXX | $2.27 0.89% 40K

Health Technology

| -46.82% | O: 0.91% H: 1.13% C: -13.29%
RIGL | $1.035 -1.43% 430K

Health Technology

| -27.59% | O: -0.69% H: 1.39% C: -7.64%
financial

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Published: 2024-03-12 (Crawled : 12:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -30.46% | O: 0.66% H: 1.32% C: -1.97%
MOR | $17.94 -0.61% 110K

Health Technology

| 0.89% | O: 0.73% H: 1.58% C: 0.83%
pharmaceuticals medical

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-05 (Crawled : 21:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -29.05% | O: 4.05% H: 12.34% C: 1.3%
business year update financial results

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Published: 2024-02-27 (Crawled : 13:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -26.06% | O: 2.11% H: 7.93% C: 3.45%
conference report business year update financial results

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
Published: 2024-01-10 (Crawled : 13:00) - globenewswire.com
AKYA | $3.82 -0.78% 110K

Professional, Scientific, and T...

| -20.87% | O: -1.39% H: 3.02% C: 2.42%
RIGL | $1.035 -1.43% 430K

Health Technology

| -23.36% | O: -1.46% H: 3.7% C: 0.74%

Rigel Pharmaceuticals Provides Business Update
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| -23.91% | O: 0.0% H: 10.14% C: 7.25%
business update pharmaceuticals

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-01-05 (Crawled : 22:00) - prnewswire.com
RIGL | $1.035 -1.43% 430K

Health Technology

| Email alert Add to watchlist
nasdaq grants

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000905148-24-000851	4	2024-03-02	2024-02-28	Buy	A	78500	78500
0000905148-24-000851	4	2024-03-02	2024-02-28	Buy	A	62500	62500